CN115776907B - Mtorc1调节剂及其用途 - Google Patents

Mtorc1调节剂及其用途 Download PDF

Info

Publication number
CN115776907B
CN115776907B CN202180038254.0A CN202180038254A CN115776907B CN 115776907 B CN115776907 B CN 115776907B CN 202180038254 A CN202180038254 A CN 202180038254A CN 115776907 B CN115776907 B CN 115776907B
Authority
CN
China
Prior art keywords
alkyl
optionally substituted
compound
formula
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180038254.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN115776907A (zh
Inventor
约翰·琴凯德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iovian Pharmaceuticals
Original Assignee
Iovian Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iovian Pharmaceuticals filed Critical Iovian Pharmaceuticals
Priority to CN202510123209.5A priority Critical patent/CN119954829A/zh
Publication of CN115776907A publication Critical patent/CN115776907A/zh
Application granted granted Critical
Publication of CN115776907B publication Critical patent/CN115776907B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Burglar Alarm Systems (AREA)
  • Pyridine Compounds (AREA)
CN202180038254.0A 2020-03-27 2021-03-26 Mtorc1调节剂及其用途 Active CN115776907B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510123209.5A CN119954829A (zh) 2020-03-27 2021-03-26 Mtorc1调节剂及其用途

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063001144P 2020-03-27 2020-03-27
US202063001177P 2020-03-27 2020-03-27
US202063001187P 2020-03-27 2020-03-27
US63/001,187 2020-03-27
US63/001,144 2020-03-27
US63/001,177 2020-03-27
US202063019176P 2020-05-01 2020-05-01
US63/019,176 2020-05-01
US202063054768P 2020-07-21 2020-07-21
US202063054763P 2020-07-21 2020-07-21
US202063054762P 2020-07-21 2020-07-21
US63/054,762 2020-07-21
US63/054,763 2020-07-21
US63/054,768 2020-07-21
PCT/US2021/024536 WO2021195599A1 (en) 2020-03-27 2021-03-26 Mtorc1 modulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510123209.5A Division CN119954829A (zh) 2020-03-27 2021-03-26 Mtorc1调节剂及其用途

Publications (2)

Publication Number Publication Date
CN115776907A CN115776907A (zh) 2023-03-10
CN115776907B true CN115776907B (zh) 2025-02-25

Family

ID=77892684

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180038254.0A Active CN115776907B (zh) 2020-03-27 2021-03-26 Mtorc1调节剂及其用途
CN202510123209.5A Pending CN119954829A (zh) 2020-03-27 2021-03-26 Mtorc1调节剂及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510123209.5A Pending CN119954829A (zh) 2020-03-27 2021-03-26 Mtorc1调节剂及其用途

Country Status (11)

Country Link
US (3) US11634432B2 (https=)
EP (1) EP4126229A4 (https=)
JP (2) JP7606591B2 (https=)
KR (2) KR20250065937A (https=)
CN (2) CN115776907B (https=)
AU (2) AU2021241718B2 (https=)
CA (1) CA3173722A1 (https=)
IL (1) IL296828A (https=)
MX (1) MX2022011964A (https=)
WO (1) WO2021195599A1 (https=)
ZA (1) ZA202210888B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241789A1 (en) 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
IL285067B2 (en) 2019-01-22 2025-02-01 Aeovian Pharmaceuticals Inc MTORC Modulators and Their Uses
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
CN115776907B (zh) 2020-03-27 2025-02-25 艾奥维安制药公司 Mtorc1调节剂及其用途
CN121426814A (zh) * 2020-07-21 2026-01-30 艾奥维安制药公司 Mtorc1调节剂及其用途
EP4688148A1 (en) * 2023-04-07 2026-02-11 Regeneron Pharmaceuticals, Inc. Selective rapamycin analogs and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007085400A1 (en) * 2006-01-24 2007-08-02 Novartis Ag Process for the preparation of rapamycin derivatives

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
SK78196A3 (en) 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US6187757B1 (en) * 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
JP2002508971A (ja) * 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
ATE264863T1 (de) * 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-epirapaloge
WO2006136175A2 (en) 2005-06-22 2006-12-28 Lifecycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
US20110098241A1 (en) 2008-04-14 2011-04-28 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
CN103391780B (zh) * 2011-02-16 2015-08-19 诺瓦提斯公司 用于治疗神经变性疾病的治疗剂的组合物
US20160138027A1 (en) * 2013-03-14 2016-05-19 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
ES2857226T3 (es) * 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
CN113620978A (zh) 2014-09-11 2021-11-09 加利福尼亚大学董事会 mTORC1抑制剂
JP6793652B2 (ja) 2015-09-03 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
US10683308B2 (en) * 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN108926533B (zh) 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 一种替西罗莫司脂质体及其制备方法
US10478561B2 (en) 2017-08-03 2019-11-19 Minhong Yu Wireless transmission system with integrated sensing capability
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
WO2019241789A1 (en) 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2020076738A2 (en) 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
HRP20250197T1 (hr) 2018-12-18 2025-04-11 Novartis Ag Derivati rapamicina
IL285067B2 (en) 2019-01-22 2025-02-01 Aeovian Pharmaceuticals Inc MTORC Modulators and Their Uses
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
CN115776907B (zh) 2020-03-27 2025-02-25 艾奥维安制药公司 Mtorc1调节剂及其用途
CN121426814A (zh) 2020-07-21 2026-01-30 艾奥维安制药公司 Mtorc1调节剂及其用途
US20220267352A1 (en) 2021-01-22 2022-08-25 Anakuria Therapeutics, Inc. Rapamycin analogs and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007085400A1 (en) * 2006-01-24 2007-08-02 Novartis Ag Process for the preparation of rapamycin derivatives

Also Published As

Publication number Publication date
US11603377B2 (en) 2023-03-14
CN115776907A (zh) 2023-03-10
US20220235069A1 (en) 2022-07-28
AU2025204768A1 (en) 2025-07-17
US20240002399A1 (en) 2024-01-04
JP7606591B2 (ja) 2024-12-25
CA3173722A1 (en) 2021-09-30
KR20250065937A (ko) 2025-05-13
JP7645431B2 (ja) 2025-03-13
WO2021195599A1 (en) 2021-09-30
EP4126229A1 (en) 2023-02-08
KR20230084095A (ko) 2023-06-12
AU2025204768B2 (en) 2025-08-07
CN119954829A (zh) 2025-05-09
AU2025204768C1 (en) 2026-02-05
IL296828A (en) 2022-11-01
US11634432B2 (en) 2023-04-25
AU2021241718A1 (en) 2022-10-20
AU2021241718B2 (en) 2025-03-27
BR112022019508A2 (pt) 2022-11-16
MX2022011964A (es) 2022-12-02
JP2025028197A (ja) 2025-02-28
EP4126229A4 (en) 2024-04-17
US20220332727A1 (en) 2022-10-20
KR102805250B1 (ko) 2025-05-08
ZA202210888B (en) 2024-02-28
JP2023530778A (ja) 2023-07-19

Similar Documents

Publication Publication Date Title
CN115776907B (zh) Mtorc1调节剂及其用途
EP2686325B1 (en) Morpholine-spirocyclic piperidine amides as modulators of ion channels
US8916565B2 (en) Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
EP2485920B1 (en) Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
AU2019280590B2 (en) Tetrahydrobenzofuro[2,3-c]pyridine and beta-carboline compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates
CA3120514A1 (en) Cyclic ureas
CN116322677B (zh) Mtorc1调节剂及其用途
CA3108809C (en) Heteroaromatic compounds, pharmaceutical compositions and uses thereof
EP3148996A1 (en) C2-carbocyclic iminothiazine dioxides as bace inhibitors, compositions, and their use
BR122024006050A2 (pt) Moduladores de mtorc1 e seus usos
BR122024006050B1 (pt) MODULADORES DE mTORC1 E SEUS USOS
BR112022019508B1 (pt) MODULADORES DE mTORC1 E SEUS USOS
WO2025185736A1 (zh) 一种多元螺环化合物的晶型、其制备方法和医药用途
JPWO2000059913A1 (ja) 新規チアゾロベンゾイミダゾール誘導体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant